Abstract
Capecitabine and docetaxel are both active against a variety of solid tumours, while their toxicity profiles only partly overlap. This phase I study was performed to determine the maximum tolerated dose (MTD) and side-effects of the combination, and to establish whether there is any pharmacokinetic interaction between the two compounds. Thirty-three patients were treated with capecitabine administered orally twice daily on days 1–14, and docetaxel given as a 1 h intravenous infusion on day 1. Treatment was repeated every 3 weeks. The dose of capecitabine ranged from 825 to 1250 mg m−2 twice a day and of docetaxel from 75 to 100 mg m−2. The dose-limiting toxicity (DLT) was asthenia grade 2–3 at a dose of 1000 mg m−2 bid of capecitabine combined with docetaxel 100 mg m−2. Neutropenia grade 3–4 was common (68% of courses), but complicated by fever in only 2.4% of courses. Other non-haematological toxicities were mild to moderate. There was no pharmacokinetic interaction between the two drugs. Tumour responses included two complete responses and three partial responses. Capecitabine 825 mg m−2 twice a day plus docetaxel 100 mg m−2 was tolerable, as was capecitabine 1250 mg m−2 twice a day plus docetaxel 75 mg m−2. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Aamdal S, Wolff I, Kaplan S, Paridaens R, Kerger R, Schachter J, Wanders J, Franklin H and Verweij J (1994) Taxotere in advanced malignant melanoma: a phase II trial of the EORTC Clinical Trials Group. Eur J Cancer 30A: 1061–1064
Aapro MS, Zulian G, Alberto P, Bruno R, Oulid-Aissa D and Le Bail N (1992) Phase I and pharmacokinetic study of RP 56976 in a new ethanol-free formulation of Taxotere. Ann Oncol 3 (suppl 5): 208
Bisset D, Setanoians A, Cassidy J, Graham MA, Chadwick GA, Wilson P, Auzannet V, Le Bail N, Kaye SB and Kerr DJ (1993) Phase I and pharmacokinetic study of Taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res 53: 523–527
Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown C and Griffin T (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17: 485–493
Ten Bokkel-Huinink WW, Prove AM, Piccart M, Steward W, Tursz T, Wanders J, Franklin H, Clavel M, Verweij J, Alaki M, Bayssas M and Kaye SB (1994) A phase II trial with docetaxel (Taxotere) in second-line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. Ann Oncol 5: 527–532
Brundage MD, Pater JL and Zee B (1993) Assessing the reliability of two toxicity scales: implications for interpretating toxicity data. J Natl Cancer Inst 85: 1138–1148
Bruno R and Sanderink GJ (1993) Pharmacokinetics and metabolism of Taxotere. In: Pharmacokinetics and Cancer Chemotherapy, Workman P, Graham MA (eds), pp. 305–313. Cold Spring Harbor Laboratory: New York, NY
Budman DR, Meropol NJ, Reigner B, Creaven PJ, Lichtman SM, Berghorn E, Behr J, Gordon RJ, Osterwalder B and Griffin T (1998) Preliminary results of a novel oral fluoropyrimidine carbamate. J Clin Oncol 16: 1795–1802
Burris H, Irvin R, Kuhn J, Kalter S, Smith L, Shaffer D, Fields S, Weiss G, Eckardt J, Rodriguez G, Rinaldi D, Wall J, Cook G, Smith S, Vreeland F, Bayssas M, Le Bail N and Von Hoff D (1993) Phase I clinical trial of Taxotere administered as either a 2-hour or 6-hour intravenous infusion every 3 weeks. J Clin Oncol 11: 950–958
Catimel G, Verweij J, Mattijsen V, Hanauske A, Piccart M, Wanders J, Franklin H, Le Bail N, Clavel M and Kaye SB (1994) Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 5: 533–537
Cerny T, Kaplan S, Pavlidis N, Schöffski P, Epelbaum R, Van Meerbeek J, Wanders J, Franklin HR and Kaye S (1994) Docetaxel (Taxotere) is active in non-small cell lung cancer: a phase II trial of the EORTC Clinical Trials Group. Br J Cancer 70: 384–387
Chevallier B, Fumoleau P, Kerbrat P, Dieras V, roche H, Krakowski I, Azli N, Bayssas M, Lentz MA and van Glabbeke M (1995) Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 13: 314–322
Extra JM, Rousseau F, Bruno R, Clavel M, Le Bail N and Marty M (1993) Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 53: 1037–1042
Findlay M, Van Cutsem E, Kocha W, Allman D, Laffranchi B, Griffin T, Osterwalder B, Dalley D, Pazdur R and Verweij J (1997) A randomized phase II study of Xeloda (Capecitabine) in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 16: 227a
De Forni M, Rougier P, Adenis A, Ducreux M, Djazouli K, Adams D, Clouet P, Blanc C, Bayssas M, Bonneterre J and Armand JP (1994) Phase II study of Taxotere in locally advanced and/or metastatic pancreatic cancer. Ann Oncol 5 (suppl 5): 509
Fossella FV, Lee JS, Shin DM, Calayag M, Huber M, Perez-Soler R, Murphy WK, Lippman S, Benner S, Glisson B, Chasen M, Ki Hong W and Raber M (1995) Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small cell lung cancer. J Clin Oncol 13: 645–651
Gueritte-Voegelein F, Guenard D, Lavelle F, Le Goff MT, Mangatal L and Poitier P (1991) Relationships between the structure of Taxol analogues and their antimitotic activity. J Med Chem 34: 992–998
Hilkens PHE, Verweij J, Stoter G, Vecht Ch, Van Putten WLJ and van den Bent MJ (1996) Peripheral neurotoxicity induced by docetaxel. Neurology 46: 104–108
Investigational drug brochure: Capecitabine (Ro 09-1978) Fourth Version, (December 1997).
Van Hoesel QGCM, Verweij J, Catimel G, Clavel M, Kerbrat P, van Oosterom AT, Kerger J, Tursz T, van Glabbeke M, Van Pottelsberghe C, Le Bail N and Mouridsen H for the EORTC Soft Tissue and Bone Sarcoma Group (1994) Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. Ann Oncol 5: 539–542
Ishikawa T, Sawada N, Sekiguchi F, Fukase Y and Ishitsuka H (1997) Xeloda™ (Capecitabine), a new oral fluoropyrimidine carbamate with an improved efficacy profile over other fluoropyrimidines. Proc Am Soc Clin Oncol 16: 226a
Khoury P, Villalona-Calero M, Blum J, Diab S, Elledge R, Kraynak M, Moczygemba J, Kromelis P, Morales I, Brown C, Griffin T, Von Hoff D and Rowinsky E (1998) Phase I study of capecitabine in combination with paclitaxel in patients with previously treated metastatic breast cancer. Proc Am Soc Clin Oncol 17: 206a
Loos WJ, Verweij J, Nooter K, Stoter G and Sparreboom A (1997) Sensitive determination of docetaxel in human plasma by liquid–liquid extraction and reversed-phase high-performance liquid chromatography. J Chromatogr B 693: 437–441
Mackean M, Planting A, Twelves C, Schellens J, Allman D, Osterwalder B, Reigner B, Griffin T, Kaye S and Verweij J (1998) Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 16: 2977–2985
Miller VA, Rigas JR, Francis PA, Grant SC, Pisters KMW, Venkatraman ES, Woolley K, Heelan RT and Kris MG (1995) Phase II trial of a 75 mg m–2dose of docetaxel with prednisone premedication for patients with advanced non-small-cell lung cancer. Cancer 75: 968–972
O’Shaugnessy J, Moiseyenko V, Bell D, Nabholtz JM, Miles D, Gorbunova V, Laws S, Griffin T and Osterwalder B (1998) A randomized phase II study of Xeloda (Capecitabine) vs CMF as first-line chemotherapy of breast cancer in women > 55 years. Proc Am Soc Clin Oncol 17: 103a
Pazdur R, Newman RA, Newman BM, Fuentes A, Benvenuto J, Bready B, Moore D, Jaiyesimi I, Vreeland F, Bayssas MMG and Raber MN (1992) Phase I trial of Taxotere: 5-day schedule. J Natl Cancer Inst 84: 1781–1788
Piccart MJ, Klijn J, Paridaens R, Nooij M, Mauriac L, Coleman R, Bontenbal M, Awada A, Selleslags J, Van Vreckem A and Van Glabbeke M (1997) Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer investigational drug branch for breast cancer. J Clin Oncol 15: 3149–3155
Pronk LC, Stoter G and Verweij J (1995) Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side effects. Cancer Treatment Rev 21: 463–478
Reigner B, Clive S, Cassidy J, Jodrell D, Schulz R, Goggin T, Banken L, Roos B, Utoh M, Mulligan T and Weidekamm E (1999) Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients. Cancer Chemother Pharmacol, (in press)
Ringel I and Horwitz SB (1991) Studies with RP 56976 (Taxotere): a semisynthetic analog of Taxol. J Natl Cancer Inst 83: 288–291
Rowinsky EK and Donehower RC (1991) The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmac Ther 52: 35–84
Rowland M and Tozer TN (1995). Clinical pharmacokinetics: concepts and applications, 3rd Edition, Media, Williams and Wilkins
Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T and Ishitsuka H (1998) Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenografts. Clin Cancer Res 4: 1013–1019
Schrijvers D, Wanders J, Dirix L, Prove A, Vonck I, Van Oosterom AT and Kaye S (1993) Coping with toxicities of docetaxel (Taxotere). Ann Oncol 4: 610–611
Sulkes A, Smyth J, Sessa C, van Oosterom AT, Vermorken J, Kaye SB, Le Bail N and Verweij J for the EORTC Early Clinical Studies Group (1994) Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. Br J Cancer 70: 380–383
Taguchi T, Ishitani K, Saitoh K, Kurihara M, Tominaga T, Fukuyama Y, Saigenji K, Toge T, Takashima S, Sugimachi K and Hara Y (1996) A Japanese phase I study of continuous twice daily treatment with capecitabine in patients with advanced and/or metastatic solid tumors. Ann Oncol 7: 87
Tomiak E, Piccart MJ, Kerger J, Lips S, Awada A, de Valeriola D, Ravoet C, Lossignol D, Sculier JP, Auzannet V, Le Bail N, Bayssas M and Klastersky J (1993) Phase I study of Taxotere (RP 56976, NSC 628503) administered as a one hour intravenous infusion on a weekly basis. J Clin Oncol 12: 1458–1467
Twelves C, Budman DR, Creaven PJ, Schellens JHM, Kuruma I, Dumont E, Osterwalder B and Reigner BG (1996) Pharmacokinetics (PK) and pharmacodynamics (PD) of capecitabine in two phase I studies. Proc Am Soc Clin Oncol 5: 476
WHO (1979). Handbook for Reporting Results of Cancer Treatment, WHO Offset Publication 48: 22–26
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Pronk, L., Vasey, P., Sparreboom, A. et al. A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours. Br J Cancer 83, 22–29 (2000). https://doi.org/10.1054/bjoc.2000.1160
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1160
Keywords
This article is cited by
-
Phase Ib trial combining capecitabine, erlotinib and bevacizumab in pancreatic adenocarcinoma - REBECA trial
Investigational New Drugs (2019)
-
Capecitabine in Combination with Docetaxel in First Line in HER2-Negative Metastatic Breast Cancer: an Observational Study
Pathology & Oncology Research (2017)
-
Phase I trial of docetaxel, oxaliplatin, and capecitabine (DOC) in untreated gastric cancer patients
International Journal of Clinical Oncology (2013)
-
Pharmacokinetic analysis of capecitabine and cisplatin in combination with trastuzumab in Japanese patients with advanced HER2-positive gastric cancer
Cancer Chemotherapy and Pharmacology (2012)
-
A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer
Cancer Chemotherapy and Pharmacology (2012)